Genfleet Pharmaceutical passed the Hong Kong Stock Exchange hearing
August 29, 2025
Source: drugdu
86
The Hong Kong Stock Exchange's official website indicates that Jinfang Pharmaceuticals (Shanghai) Co., Ltd. has passed its hearing and is poised to list on the Hong Kong Stock Exchange. The prospectus states that Jinfang Pharmaceuticals, founded in 2017, is a biopharmaceutical company focused on developing novel treatment options for oncology (covering various lines of treatment for various solid tumors) as well as autoimmune and inflammatory diseases. Currently, Jinfang Pharmaceuticals has established a product pipeline consisting of eight drug candidates, five of which are in clinical development.
Comment: Jinfang Pharmaceuticals, which has passed its Hong Kong Stock Exchange hearing, focuses on oncology and immune diseases. Its pipeline includes eight drug candidates, five of which are in clinical trials. A successful IPO could accelerate R&D, but the company faces intense competition in the field.
https://finance.eastmoney.com/a/202508273495486977.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
